Targeting infections within the gastrointestinal tract

Advanced Drug Formulation Design to Optimize Therapeutic Outcomes

Volumn , Issue , 2007, Pages 217-244

  Batchelor, Hannah ^a   Conway, Barbara ^a  

^a ASTON UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 82255175760     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (52)

1. Lupetti A, Danesi R, van’t Wout JW, van Dissel JT, Senesi S, Nibbering PH. Antimicrobial peptides: therapeutic potential for the treatment of Candida infections. Expert Opin Invest Drugs 2002; 11:309–18.
2. Salamat-Miller N, Chittchang M, Johnston TP. The use of mucoadhesive polymers in buccal drug delivery. Adv Drug Deliv Rev 2005; 57:1666–91.
3. Christrup LL, David SS, Frier M, et al. Deposition of a model substance, 99mTc E-HIDA, in the oral cavity after administration of lozenges, chewing gum and sublingual tablets. Int J Pharm 1990; 66(1–3):169–174.
4. Martins MD, Rex JH. Fluconazole suspension for oropharyngeal candidiasis unresponsive to tablets. Ann Internal Med 1997; 126(4):332–3(Abstract).
5. Senel S, Ikinci G, Kas S, Yousefi-Rad A, Sargon MF, Hincal AA. Chitosan films and hydrogels of chlorhexidine gluconate for oral mucosal delivery. Int J Pharmaceut 2000; 193:197–203.
6. deVries-Hospers HG, vander WD. Amphotericin B concentrations in saliva after application of 2% amphotericin B in orabase. Infection 1978; 6:16–20.
7. Nafee NA, Ismail FA, Boraie NA, Mortada LM. Mucoadhesive buccal patches of miconazole nitrate: in vitro/in vivo performance and effect of ageing. Int J Pharm 2003; 264:1–14.
8. Bouckaert S, Remon JP. In-vitro bioadhesion of a buccal, miconazole slow-release tablet. J Pharm Pharmacol 1993; 45:504–7.
9. Khanna R, Agarwal SP, Ahuja A. Preparation and evaluation of bioerodible buccal tablets containing clotrimazole. Int J Pharm 1996; 138:67–73.
10. Senel S, Ikinci G, Kas S, Yousefi-Rad A, Sargon MF, Hincal AA. Chitosan films and hydrogels of chlorhexidine gluconate for oral mucosal delivery. Int J Pharm 2000; 193:197–203.
11. Giunchedi P, Juliano C, Gavini E, Cossu M, Sorrenti M. Formulation and in vivo evaluation of chlorhexidine buccal tablets prepared using drug-loaded chitosan microspheres. Eur J Pharm Biopharm 2002; 53:233–9.
12. Carlo CG, Bergamante V, Calabrese V, Biserni S, Ronchi C, Fini A. Design and evaluation in vitro of controlled release mucoadhesive tablets containing chlorhexidine. Drug Dev Ind Pharm 2006; 32:53–61.
13. Van RJ, Haxaire M, Kamya M, Lwanga I, Katabira E. Comparative efficacy of topical therapy with a slow-release mucoadhesive buccal tablet containing miconazole nitrate versus systemic therapy with ketoconazole in HIV-positive patients with oropharyngeal candidiasis. J Acquir Immune Defic Syndr 2004; 35:144–50.
14. Bouckaert S, Schautteet H, Lefebvre RA, Remon JP, van CR. Comparison of salivary miconazole concentrations after administration of a bioadhesive slow-release buccal tablet and an oral gel. Eur J Clin Pharmacol 1992; 43: 137–40.
15. Mohammed FA, Khedr H. Preparation and in vitro/in vivo evaluation of the buccal bioadhesive properties of slow-release tablets containing miconazole nitrate. Drug Dev Ind Pharm 2003; 29:321–37.
16. Cardot JM, Chaumont C, Dubray C, Costantini D, Aiache JM. Comparison of the pharmacokinetics of miconazole after administration via a bioadhesive slow release tablet and an oral gel to healthy male and female subjects. Br J Clin Pharm 2004; 58:345–51.
17. Habib W, Khankari R, Hontz J. Fast-dissolve drug delivery systems. Crit Rev Ther Drug Carrier Syst 2000; 17:61–72.
18. Vandercam B, Gibbs D, Valtonen M, JSger H, Armignacco O. Fluconazole orally dispersible tablets for the treatment of patients with oropharyngeal candidiasis. J Int Med Res 1998; 26(4):209–18 (Abstract).
19. Addy M, Roberts WR. Comparison of the bisbiguanide antiseptics alexidine and chlorhexidine. II. Clinical and in vitro staining properties. J Clin Periodontol 1981; 8:220–30.
20. Andersen T, Gram-Hansen M, Pedersen M, Rassing MR. Chewing gum as a drug delivery system for nystatin. Influence of solubilising agents on the release of water-soluble drugs. Drug Dev Ind Pharm 1990; 16: 1985–94.
21. Bastian HL, Rindum J, Lindeberg H. A double-dummy, double-blind, placebo-controlled phase III study comparing the efficacy and efficiency of miconazole chewing gum with a known drug (Brentan gel) and a placebo in patients with oral candidosis. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2004; 98:423–8.
22. Emslie RD. Treatment of acute ulcerative gingivitis. A clinical trial using chewing gums containing metronidazole or penicillin. Br Dent J 1967; 122: 307–8.
23. Rindum JL, Holmstrup P, Pedersen M, Rassing MR, Stoltze K. Miconazole chewing gum for treatment of chronic oral candidosis. Scand J Dent Res 1993; 101:386–90.
24. Pavelic RA. Use of an analgesic-antibiotic chewing troche (orabitic) in post-tonsillectomy and adenoidectomy complications. Eye Ear Nose Throat Mon 1960; 39:644–5.
25. Codd JE, Deasy PB. Formulation development and in vivo evaluation of a novel bioadhesive lozenge containing a synergistic combination of antifungal agents. Int J Pharm 1998; 173:13–24.
26. Bromberg LE, Buxton DK, Friden PM. Novel periodontal drug delivery system for treatment of periodontitis. J Control Release 2001; 71:251–9.
27. Gorman SP, McCafferty DF, Woolfson AD, Jones DS. A comparative study of the microbial antiadherence capacities of three antimicrobial agents. J Clin Pharm Ther 1987; 12:393–9.
28. Tobgi RS, Samaranayake LP, MacFarlane TW. Adhesion of Candida albicans to buccal epithelial cells exposed to chlorhexidine gluconate. J Med Vet Mycol 1987; 25:335–8.
29. Barembaum S, Virga C, Bojanich A, et al. Effect of Chitosan and Sodium Alginate on the adherence of autochthonous C. Albicans to oral epithelial cells (in vitro). Med Oral 2003; 8:188–96.
30. McCarron PA, Donnelly RF, Canning PE, McGovern JG, Jones DS. Bioadhesive, non-drug-loaded nanoparticles as modulators of candidal adherence to buccal epithelial cells: a potentially novel prophylaxis for candidosis. Biomaterials 2004; 25:2399– 407.
31. Laine L, Dretler RH, Conteas CN, et al. Fluconazole compared with ketoconazole for the treatment of Candida esophagitis in AIDS. A randomized trial. Ann Intern Med 1992; 117:655–60.
32. Rex JH, Rinaldi MG, Pfaller MA. Resistance of Candida species to fluconazole. Antimicrobial Agents Chemother 1995; 39(1):1–8.
33. Wilcox CM, Darouiche RO, Laine L, Moskovitz BL, Mallegol I, Wu J. A randomized, double-blind comparison of itraconazole oral solution and fluconazole tablets in the treatment of esophageal candidiasis. J Infect Dis 1997; 176:227–32.
34. Laine L, Rabeneck L. Prospective study of fluconazole suspension for the treatment of oesophageal candidiasis in patients with AIDS. Aliment. Pharmacol Ther 1995; 9:553–6.
35. Megraud F. Strategies to treat patients with antibiotic resistant Helicobacter pylori. Int J Antimicrob Agents 2000; 16:507–9.
36. Goddard AF, Erah PO, Barrett DA, Shaw PN, Spiller RC. The effect of protein binding and lipophilicity of penicillins on their in-vitro flux across gastric mucosa. J Antimicrobial Chemother 1998; 41:231–6.
37. Nakamura M, Spiller RC, Barrett DA, et al. Gastric juice, gastric tissue and blood antibiotic concentrations following omeprazole, amoxicillin and claithromycin triple therapy. Helicobacter 2003; 6:294–9.
38. Erah PO, Goddard AF, Barrett DA, Shaw PN, Spiller RC. The stability of amoxicillin, clarithromycin and metronidazole in gastric juice: relevance to the treatment of Helicobacter pylori infection. J Antimicrob Chemother 1997; 39: 5–12.
39. Lehr C-M, Bouwstra JA, Schacht EH, Junginger HE. In vitro evaluation of mucoadhesive properties of chitosan and some other natural polymers. Int J Pharm 2006; 78:43–8.
40. Gaserød O, Joliffe IJ, Hampson FC, Dettmar PW, Skja˚k-Bræk G. The enhancement of the bioadhesive properties of alginate gel beads by coating with chitosan. Int J Pharmaceut 1998; 175:237–46.
41. Chandy T, Sharma CP. Chitosan matrix for oral sustained delivery of ampicillin. Biomaterials, 1993; 14:939–44.
42. Klausner EA, Lavy E, Friedman M, Hoffman A. Expandable gastroretentive dosage forms. J Control Release 2003; 90:143–62.
43. Chen J, Blevins WE, Park H, Park K. Gastric retention properties of superporous hydrogel composites. J Control Release 2000; 64:39–51.
44. Marchetti M, Rossi M, Gianelli V, et al. Protection against Helicobacter pylori infection in mice by intragastric vaccination with H. pylori antigens is achieved using a non-toxic mutant of E. coli heat-labile enterotoxin (LT) as adjuvant. Vaccine 1998; 16:33–7.
45. Vajdy M, Singh M, Ugozzoli M, et al. Enhanced mucosal and systemic immune responses to Helicobacter pylori antigens through mucosal priming followed by systemic boosting immunizations. Immunology 2003; 100:86–94.
46. Rugiero P, Peppoloni S, Rappuoli R, Del Guidice G. The quest for a vaccine against Helicobacter pylori: how to move from mouse to man? Microbial Infect 2003; 5:749–56.
47. Sutton P, Doidge C. Helicobacter vaccines spiral into the new millennium. Digestive Liver Dis 2003; 25:675–87.
48. Stanley J. Amoebiasis. The Lancet 2003; 361:1025–34.
49. Rudnic EM, Isbister JD, Treacy DJ, Wassink SE. Antibiotic product, use and formulation thereof US Patent No. 6,723,341, 2004 http://www.patentstorm. us/patents/6723341.html.
50. Mortazavi SA, Smart JD. An investigation of some factors influencing the in vitro assessment of mucoadhesion. Int J Pharm 1995; 116:223–30.
51. Henrisksen I, Green KL, Smart JD, Smistad G, Karlsen J. Bioadhesion of hydrated chitosans: An in vitro and in vivo study. Int J Pharm 1996; 145: 231–40.
52. Kayser O. A new approach for targeting to Cryptosporidium parvum using mucoadhesive nanosuspensions: research and applications. Int J Pharm 2001; 214:83–5.